血浆氧化三甲胺水平与心房颤动相关

doi:10.16352/j.issn.1001-6325.2025.04.0499

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (4): 499-504.doi: 10.16352/j.issn.1001-6325.2025.04.0499

血浆氧化三甲胺水平与心房颤动相关

杨文涛¹, 赵清², 李向东², 王玉堂^3*, 刘巍^1*

1.首都医科大学附属北京积水潭医院心血管内科,北京 100035;
2.解放军总医院第一医学中心心血管内科,北京 100853;
3.解放军总医院第二医学中心心血管内科　国家老年疾病临床医学研究中心,北京 100853

收稿日期:2024-12-24 修回日期:2025-02-20 出版日期:2025-04-05 发布日期:2025-03-24
通讯作者: ^*wangyutang301@126.com; liuwei525@hotmail.com
基金资助:
北京自然科学基金(Z141100002114050)

Association between plasma trimethylamine N-oxide level and atrial fibrillation

YANG Wentao¹, ZHAO Qing², LI Xiangdong², WANG Yutang^3*, LIU Wei^1*

1. Department of Cardiology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035;
2. Department of Cardiology, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853;
3. Department of Cardiology, the Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese People's Liberation Army General Hospital, Beijing 100853, China

Received:2024-12-24 Revised:2025-02-20 Online:2025-04-05 Published:2025-03-24

摘要/Abstract

摘要： 目的　探讨血浆氧化三甲胺(TMAO)水平与心房颤动(AF)之间的关联。方法　共纳入257例AF患者,其中阵发性 AF 114 例、持续性 AF 143例;以及122例非 AF 患者作为对照;测量血浆TMAO水平并收集患者的人口特征及临床资料,进行回归分析以探索血浆 TMAO水平与AF是否有关联。结果　AF患者的血浆TMAO水平高于非AF患者(3.9[2.4~5.9]vs. 2.4[1.6~3.7]μmol/L, P＜0.001);经过年龄、糖尿病、高血压、心力衰竭、身体质量指数的多因素校正,TMAO水平仍与AF显著相关(OR:1.29,95% CI:1.151~1.445;P＜0.001);在AF患者中,持续性AF患者血浆中的TMAO水平高于阵发性AF组(4.4[2.8~6.8]vs. 3.2[2.2~5.0]μmol/L,P＜0.01);经过年龄、高血压、糖尿病、心力衰竭、冠心病的多因素校正,血浆TMAO水平与持续性AF仍存在关联(OR:1.092,95% CI:1.009~1.182;P=0.029)。结论　AF患者的血浆 TMAO水平高于非AF患者,升高的血浆 TMAO 水平与AF风险增加相关;在AF患者中,血浆TMAO水平升高与持续性AF的风险增加相关。

关键词: 氧化三甲胺, 心房颤动, 阵发性房颤, 持续性房颤

Abstract: Objective To explore the relationship between plasma trimethylamine N-oxide(TMAO) level and atrial fibrillation(AF) by a clinical trial. Methods Totally 257 patients with AF were enrolled including 114 patients with paroxysmal AF and 143 with persistent AF. The control group had 122 non-AF patients; Plasma TMAO level, the demographic characteristics and clinical data of patients were collected. Regression analysis was performed to identify the association between TMAO and presence of AF. Results Plasma TMAO level of patients with AF was higher than that of patients without AF(3.9[2.4-5.9]vs. 2.4[1.6-3.7]μmol/L,P＜0.001);Even after adjust-ment of confounding factors including age, hypertension, diabetes, heart failure and body mass index; Plasma TMAO level was still related to presence of AF(OR:1.290,95% CI:1.151-1.445;P＜0.001).The plasma TMAO level of patients with persistent AF was higher than that of patients with paroxysmal AF(4.4[2.8-6.8]vs. 3.2[2.2-5.0]μmol/L,P＜0.01); Even after adjustment of confounding factors including age, hypertension, diabetes and heart failure and coronary heart disease; Plasma TMAO level was still related to persistent AF(OR:1.092,95% CI:1.009-1.182;P=0.029). Conclusions The level of plasma TMAO of patients with AF is higher than that of patients without AF. Elevated plasma TMAO level is related to an increased risk of AF. Elevated plasma TMAO level in patients with AF is related to an increased risk of persistent AF.

Key words: trimethylamine N-oxide, atrial fibrillation, paroxysmal atrial fibrillation, persistent atrial fibrillation

中图分类号:

R541.7

杨文涛, 赵清, 李向东, 王玉堂, 刘巍. 血浆氧化三甲胺水平与心房颤动相关[J]. 基础医学与临床, 2025, 45(4): 499-504.

YANG Wentao, ZHAO Qing, LI Xiangdong, WANG Yutang, LIU Wei. Association between plasma trimethylamine N-oxide level and atrial fibrillation[J]. Basic & Clinical Medicine, 2025, 45(4): 499-504.

参考文献

[1] Kornej J, Borschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights[J]. Circ Res, 2020,127:4-20.
[2] Tang W, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure[J]. Nat Rev Cardiol, 2019,16:137-154.
[3] Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease[J]. Circ Res, 2020,127:553-570.
[4] Luqman A, Hassan A, Ullah M, et al. Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder[J]. Front Immunol, 2024,15:1321395.doi: 10.3389/fimmu.2024.1321395.
[5] Gawalko M, Agbaedeng TA, Saljic A, et al. Gut microbiota, dysbiosis and atrial fibrillation. arrhythmogenic mechanisms and potential clinical implications[J].Cardiovasc Res, 2022,118:2415-2427.
[6] Linz D, Gawalko M, Sanders P, et al. Does gut microbiota affect atrial rhythm? causalities and specula-tions[J]. Eur Heart J, 2021,42:3521-3525.
[7] Svingen G, Zuo H, Ueland PM, et al. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation[J]. Int J Cardiol, 2018,267:100-106.
[8] Papandreou C, Bullo M, Hernandez-Alonso P, et al. Choline metabolism and risk of atrial fibrillation and heart failure in the PREDIMED Study[J]. Clin Chem, 2021,67:288-297.
[9] Nguyen BO, Meems L, van Faassen M, et al. Gut-microbe derived TMAO and its association with more progressed forms of AF: results from the AF-RISK study[J]. Int J Cardiol Heart Vasc, 2021,34:100798.doi: 10.1016/j.ijcha.2021.100798.
[10] Buttner P, Okun JG, Hauke J, et al. Trimethylamine N-oxide in atrial fibrillation progression[J]. Int J Cardiol Heart Vasc, 2020,29:100554.doi:10.1016/j.ijcha.2020.100554.
[11] Guo Y, Wang Y, Li X, et al. Optimal thromboprophylaxis in elderly Chinese patients with atrial fibrillation(ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study[J]. BMJ Open, 2018,8:e20191.doi: 10.1136/bmjopen-2017-020191.
[12] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J, 2021,42:373-498.
[13] Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis[J]. J Clin Epidemiol, 1996,49:1373-1379.
[14] Pelletier CC, Croyal M, Ene L, et al. Elevation of trimethylamine-N-oxide in chronic kidney disease: contribution of decreased glomerular filtration rate[J]. Toxins(Basel), 2019,11:635. doi: 10.3390/toxins11110635.
[15] Gawalko M, Jespersen T, Dobrev D, et al. The gut microbial-derived metabolite trimethylamine N-oxide: a missing link between lifestyle-components and atrial fibrillation?[J]. Int J Cardiol Heart Vasc, 2020,29:100581. doi: 10.3390/toxins11110635.

编辑推荐 0

Metrics

阅读次数

全文

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	11

	来源	本网站

	次数	11
	比例	100%

摘要

最新录用	在线预览	正式出版

0	0	38

	来源	本网站

	次数	38
	比例	100%

血浆氧化三甲胺水平与心房颤动相关

Association between plasma trimethylamine N-oxide level and atrial fibrillation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐 0

Metrics

本文评价

[1]	杨晴, 梁岩. 以患者为中心的AF-CARE管理路径:《2024欧洲心脏病学会房颤管理指南》热点探讨[J]. 基础医学与临床, 2025, 45(2): 142-147.
[2]	郭爽, 李树仁, 赵美, 郝潇. 连接蛋白2和FGF23在房颤介导心肌病兔心房组织中的表达[J]. 基础医学与临床, 2024, 44(2): 199-203.
[3]	杨多军, 刘静涵. 心电图P波特征与急性心肌梗死患者新发房颤相关[J]. 基础医学与临床, 2024, 44(11): 1569-1572.
[4]	缪昊真, 陶磊, 宋冰洁, 张奇军. 代谢重编程在心房颤动发生中作用的研究进展[J]. 基础医学与临床, 2023, 43(11): 1718-1722.
[5]	何丹, 阮中宝. 细胞外囊泡在心房颤动发病中的作用[J]. 基础医学与临床, 2022, 42(4): 671-674.
[6]	凌云钟国强李金轶何燕张景昌宋红星熊日新. 迷走神经与心房颤动犬上腔静脉肌袖内缝隙连接重构[J]. 基础医学与临床, 2010, 30(5): 510-514.
[7]	高崇瀚宋凌鲲李凡戴引殷跃辉. 甲状腺素对犬心房电生理特征和连接蛋白Cx43的影响[J]. 基础医学与临床, 2009, 29(10): 1092-1096.